VENUS REMEDIES share price has plunged 9% and is presently trading at Rs 312.8.
Meanwhile, the BSE HEALTHCARE index is at 43,014.1 (down 0.5%).
Among the top losers in the BSE HEALTHCARE index today are Cipla (down 3.7%) and Torrent Pharma (down 2.6%).
POLY MEDICURE (up 4.1%) and FDC (up 1.9%) are among the top gainers today.
Over the last one year, VENUS REMEDIES has moved up from Rs 273.3 to Rs 312.8, registering a gain of Rs 39.5 (up 14.4%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,385.2 to 43,014.1, registering a gain of 57.1% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 185.5%), SUVEN PHARMACEUTICALS (up 125.7%) and Glenmark Pharma (up 123.3%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 80,029.1 (down 0.4%).
The top losers among the BSE Sensex today are ICICI Bank (down 1.6%) and Sun Pharma (down 1.6%). The most traded stocks in the BSE Sensex are Power Grid Corp. and Tata Motors.
In the meantime, NSE Nifty is at 24,416.6 (down 0.2%). Cipla and Dr. Reddys are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 64,112.7 to 80,029.1, registering a gain of 15,916.5 points (up 24.8%).
VENUS REMEDIES net profit grew 3.4% YoY to Rs 12 million for the quarter ended June 2024, compared to a profit of Rs 12 million a year ago. Net sales rose 14.1% to Rs 1,086 million during the period as against Rs 952 million in April-June 2023.
For the year ended March 2024, VENUS REMEDIES reported 7.2% increase in net profit to Rs 285 million compared to net profit of Rs 266 million during FY23. Revenue of the company grew 8.3% to Rs 6,014 million during FY24.
The current Price to earnings ratio of VENUS REMEDIES, based on rolling 12 month earnings, stands at 14.7.
Equitymaster requests your view! Post a comment on "VENUS REMEDIES Plunges 9%; BSE HEALTHCARE Index Down 0.5%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!